Breast Cancer With Over-expression of erbB2 Study of the Treatment Paradigm in Metastasis to BRAIN (BRAINSTORM)
N/A
N/A
N/A
N/A
N/A
Not Enrolling
Female
Cancer, Breast Cancer
Female
Cancer, Breast Cancer
Trial Information
Breast Cancer With Over-expression of erbB2 Study of the Treatment Paradigm in Metastasis to BRAIN (BRAINSTORM)
Inclusion Criteria:
1. Female patients diagnosed with erbB2+ breast cancer. ErbB2 positivity will be as
determined by respective institutional standards, and will be based on medical
history only.
2. Brain metastasis diagnosis made between January 2006 - December 2008.
Exclusion Criteria:
1. Women who have another primary cancer diagnosed between the time of breast cancer
diagnosis and brain metastasis..
2. Patient has leptomeningeal metastases only without parenchymal brain involvement
(since this pattern of the disease requires a different treatment approach.)
Type of Study:
Observational
Study Design:
Observational Model: Cohort, Time Perspective: Retrospective
Outcome Measure:
To describe the treatment pattern of brain metastasis in ErbB2 over-expressing breast cancer in Asia Pacific countries.
Outcome Time Frame:
Time (in months) from date of first diagnosis of brain metastasis through to death or end of study period
Safety Issue:
No
Principal Investigator
GSK Clinical Trials
Investigator Role:
Study Director
Investigator Affiliation:
GlaxoSmithKline
Authority:
United Kingdom: GSK Observational Study
Study ID:
113349
NCT ID:
NCT01064349
Start Date:
May 2009
Completion Date:
July 2011
Related Keywords:
- Cancer
- Breast Cancer
- ErbB2+ breast cancer
- ErbB2 treatment
- brain metastases
- Breast Neoplasms
Name | Location |
|---|
